Angiochem

Angiochem is a clinical-stage biotechnology company headquartered in Montreal, Canada, founded in 2003. The company is focused on discovering and developing a new class of pharmaceuticals — peptide drug conjugates — designed to cross the blood-brain barrier (BBB) by leveraging the LRP-1 (low-density lipoprotein receptor-related protein 1) mediated pathway. This approach is intended to address a fundamental physiological obstacle that has historically blocked effective treatment of central nervous system (CNS) diseases. Angiochem's pipeline spans both small molecules and biologics, targeting a wide range of CNS conditions. Its stated therapeutic areas include primary brain cancer and brain metastases (oncology), moderate to severe pain, and lysosomal storage diseases (LSDs) such as Tay-Sachs disease, Fabry disease, Gaucher's disease, Pompe disease, Hunter syndrome and other mucopolysaccharidoses. The company describes its products as "beyond barriers," reflecting the core scientific premise that its conjugates can deliver therapeutic payloads into the brain. Among its lead programs, ANG1005 has demonstrated anti-cancer activity in early-stage clinical trials for primary brain cancers and cancers that have metastasized to the brain. ANG2002 is being developed as a potential first-in-class analgesic for cancer pain, post-operative pain and neuropathic pain, with the aim of avoiding the side effects associated with opiates. The company also maintains a broader pipeline and engages in partnering activities with pharmaceutical and biotechnology collaborators. Angiochem operates as a private, clinical-stage company and maintains a bilingual (English and French) corporate presence consistent with its Montreal base. In June 2019 the company announced it had received a loan from the Quebec government to support a Phase III clinical trial, underscoring both its late-stage ambitions and its ties to the Quebec life-sciences ecosystem. The company's website highlights its technology platform, pipeline, partnering opportunities, publications and news, positioning Angiochem as a platform-driven CNS drug developer rather than a commercial-stage pharmaceutical manufacturer.

Angiochem was founded in 2003 and established its headquarters in Montreal, Canada. From its inception, the company pursued a differentiated scientific strategy: rather than attempting to modify drugs to passively diffuse into the brain, it built a platform around the LRP-1 mediated pathway, a biological transport mechanism that can carry conjugated therapeutic molecules across the blood-brain barrier. This platform became the foundation for a pipeline of peptide drug conjugates intended to treat neurological diseases that are otherwise difficult to address because of the BBB. Over the years, Angiochem assembled a pipeline spanning oncology, pain and lysosomal storage diseases. Its lead oncology candidate, ANG1005, advanced into clinical testing and, according to the company, demonstrated anti-cancer activity in early-stage clinical trials involving primary brain cancers and cancers that metastasized to the brain. A second program, ANG2002, was developed as a potential first-in-class analgesic intended to manage moderate to severe cancer pain, post-operative pain and neuropathic pain without the side effects of opiates. The company also described development efforts in lysosomal storage diseases, a group of rare inherited disorders including Tay-Sachs disease, Fabry disease, Gaucher's disease, Pompe disease, Hunter syndrome and other mucopolysaccharidoses. Angiochem has operated as a private, clinical-stage biotechnology company and has engaged in partnering activities, offering its technology platform and pipeline programs to potential pharmaceutical and biotechnology collaborators. Its corporate communications are bilingual in English and French, reflecting its Montreal base and its integration into the Quebec life-sciences cluster. A notable recent milestone came in June 2019, when Angiochem announced that it had received a loan from the Quebec government to perform a Phase III clinical trial. This support signaled both the company's progression toward late-stage clinical development and the backing of provincial authorities for its CNS-focused programs. The company continues to present itself as a platform-driven developer of pharmaceuticals that "go beyond barriers," with a focus on crossing the blood-brain barrier to reach unmet medical needs in the central nervous system.

• 2019

  Angiochem receives a loan from the Quebec government to perform a Phase III clinical trial (announced 5 June 2019).

• 2003

  Angiochem founded; headquarters established in Montreal, Canada.

• ANG1005 demonstrates anti-cancer activity in early-stage clinical trials for primary brain cancer and brain metastases.

• ANG2002 developed as a potential first-in-class analgesic without opiate side effects.

Clinical-stage CNS-focused biotechnology company developing peptide drug conjugates that cross the blood-brain barrier via the LRP-1 pathway, targeting brain cancer, pain and lysosomal storage diseases.

• ANG1005

  Oncology peptide drug conjugate that has demonstrated anti-cancer activity in early-stage clinical trials for primary brain cancers and cancers metastasized to the brain.

• ANG2002

  Potential first-in-class analgesic for moderate to severe cancer pain, post-operative pain and neuropathic pain, designed without the side effects of opiates.

• LRP-1 BBB-crossing platform

  Technology platform using the LRP-1 mediated pathway to transport peptide drug conjugates across the blood-brain barrier.

1. 1AngioChem | tsa hdac inhibitor | Peptide-Antibody Conjugates that Cross the Blood Brain Barrierangiochem.com
2. 2About Angiochem | Angiochem: Peptide-Antibody Conjugates that Cross the Blood Brain Barrierangiochem.com
3. 3Products | Angiochem: Peptide-Antibody Conjugates that Cross the Blood Brain Barrierangiochem.com
4. 4Angiochem (Canada) - Wikidatawikidata.org